AU723860B2 - Azolobenzazepine derivatives as neurologically active agents - Google Patents

Azolobenzazepine derivatives as neurologically active agents Download PDF

Info

Publication number
AU723860B2
AU723860B2 AU22253/97A AU2225397A AU723860B2 AU 723860 B2 AU723860 B2 AU 723860B2 AU 22253/97 A AU22253/97 A AU 22253/97A AU 2225397 A AU2225397 A AU 2225397A AU 723860 B2 AU723860 B2 AU 723860B2
Authority
AU
Australia
Prior art keywords
alkyl
phenyl
alkoxy
dione
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU22253/97A
Other languages
English (en)
Other versions
AU2225397A (en
Inventor
Kelly Anne Brush
Marc Jerome Chapdelaine
William Jackson Frazee
Laura Enid Garcia-Davenport
Joseph James Lewis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of AU2225397A publication Critical patent/AU2225397A/en
Application granted granted Critical
Publication of AU723860B2 publication Critical patent/AU723860B2/en
Assigned to ASTRAZENECA AB reassignment ASTRAZENECA AB Alteration of Name(s) in Register under S187 Assignors: ZENECA LIMITED
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU22253/97A 1996-03-08 1997-03-04 Azolobenzazepine derivatives as neurologically active agents Ceased AU723860B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1352896P 1996-03-08 1996-03-08
US60/013528 1996-03-08
PCT/GB1997/000592 WO1997032883A1 (en) 1996-03-08 1997-03-04 Azolobenzazepine derivatives as neurologically active agents

Publications (2)

Publication Number Publication Date
AU2225397A AU2225397A (en) 1997-09-22
AU723860B2 true AU723860B2 (en) 2000-09-07

Family

ID=21760422

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22253/97A Ceased AU723860B2 (en) 1996-03-08 1997-03-04 Azolobenzazepine derivatives as neurologically active agents

Country Status (13)

Country Link
US (2) US6124281A (enExample)
EP (1) EP0888350A1 (enExample)
JP (1) JP2000506160A (enExample)
KR (1) KR19990087585A (enExample)
CN (1) CN1084747C (enExample)
AU (1) AU723860B2 (enExample)
CA (1) CA2247453A1 (enExample)
IL (1) IL126095A0 (enExample)
NO (1) NO984106L (enExample)
NZ (1) NZ330973A (enExample)
TW (1) TW486480B (enExample)
WO (1) WO1997032883A1 (enExample)
ZA (1) ZA971964B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100389140B1 (ko) * 1997-09-29 2003-06-25 메이지 세이카 가부시키가이샤 삼환성 트리아졸로벤즈아제핀 유도체 및 그의 제조방법 및항알레르기제
US7919109B2 (en) * 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7002009B2 (en) 2001-12-26 2006-02-21 Meiji Seika Kaisha, Ltd. Crystalline tricyclic triazolobenzazepine derivative
AU2003212979A1 (en) * 2002-02-07 2003-09-02 Neurogen Corporation Substituted fused pyrazolecarboxylic acid arylamides and related compounds
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
HRP20080120T5 (hr) 2004-05-14 2012-07-31 Millennium@Pharmaceuticals Spojevi i postupci za inhibiciju napredovanja mitoze s pomoću inhibicije aurora kinaze
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
EP2359808B1 (en) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CN104000779A (zh) 2007-04-23 2014-08-27 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
WO2010074724A1 (en) 2008-12-22 2010-07-01 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd20 antibodies
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
RU2753280C2 (ru) 2009-09-28 2021-08-12 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
RU2012140021A (ru) 2010-02-19 2014-03-27 Миллениум Фармасьютикалз, Инк. КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНИЛ)-5Н-ПИРИМИДО[5,4-d][2]БЕНЗАЗЕПИН-2-ИЛ]АМИНО}-2-МЕТОКСИБЕНЗОАТА НАТРИЯ
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
EP2976086B1 (en) 2013-03-22 2020-10-14 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2016196851A2 (en) 2015-06-03 2016-12-08 Intarcia Therapeutics, Inc. Implant placement and removal systems
EP3324976A4 (en) 2015-07-21 2019-03-27 Millennium Pharmaceuticals, Inc. ADMINISTRATION OF KINASE AURORA INHIBITOR AND CHEMOTHERAPEUTIC AGENTS
JP7077237B2 (ja) 2016-05-16 2022-05-30 インターシア セラピューティクス，インコーポレイティド グルカゴン受容体選択的ポリペプチド及びその使用方法
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0686636A1 (en) * 1993-12-28 1995-12-13 Meiji Seika Kabushiki Kaisha Tricyclic benzazepine and benzothiazepine derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9311948D0 (en) * 1993-06-10 1993-07-28 Zeneca Ltd Substituted nitrogen heterocycles
WO1997000258A1 (en) * 1995-06-15 1997-01-03 Meiji Seika Kabushiki Kaisha Tricyclic benzazepine compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0686636A1 (en) * 1993-12-28 1995-12-13 Meiji Seika Kabushiki Kaisha Tricyclic benzazepine and benzothiazepine derivatives

Also Published As

Publication number Publication date
ZA971964B (en) 1997-09-08
KR19990087585A (ko) 1999-12-27
NZ330973A (en) 2000-03-27
EP0888350A1 (en) 1999-01-07
CA2247453A1 (en) 1997-09-12
US6313290B1 (en) 2001-11-06
JP2000506160A (ja) 2000-05-23
NO984106L (no) 1998-11-06
CN1084747C (zh) 2002-05-15
CN1224424A (zh) 1999-07-28
NO984106D0 (no) 1998-09-07
IL126095A0 (en) 1999-05-09
AU2225397A (en) 1997-09-22
WO1997032883A1 (en) 1997-09-12
US6124281A (en) 2000-09-26
TW486480B (en) 2002-05-11

Similar Documents

Publication Publication Date Title
AU723860B2 (en) Azolobenzazepine derivatives as neurologically active agents
AU2017371200B2 (en) Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
EP0225013B1 (en) Heterocyclic compounds and their preparation and use
RU2378277C2 (ru) Производные пиразолпиримидина
JP2007217419A (ja) 高血圧症の治療に有用な５，７−ジアミノピラゾロ４，３−ジピリミジン類
US4873244A (en) Tricyclic heterocyclic compounds as psychopharmaceuticals
EP3360876A1 (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
EA002755B1 (ru) Производные триазолопиридазина в качестве лигандов для гамк рецепторов
KR20190039781A (ko) 스피로환 함유 화합물 및 이의 약제학적 용도
JP2001507705A (ja) ３−アリル置換ピラゾロ［４，３−ｄ］ピリミジン誘導体；コルチコトロピン放出因子レセプタ（ＣＲＦ▲下１▼）特異リガンド
CA2388658A1 (en) 1-amino triazolo[4,3-a]quinazolin-5-ones and or -5-thiones inhibiting phosphodiesterase iv
EP0320136B1 (en) Imidazoquinoxaline compounds and their preparation and use
TW201702247A (zh) 作為ｔｎｆ信號傳遞調節劑之吲唑酮
HUP0102894A2 (hu) Helyettesített triazolopiridazin-származék, valamint ilyen vegyületet tartalmazó gyógyászati készítmények
EP0197282A1 (en) Novel oxadiazolyl imidazobenzodiazepine derivatives and methods of preparing such compounds
DE69907923T2 (de) Triazolopyridazinderivate zur verbesserung der kognitiven funktionen
JPH09510727A (ja) イミダゾ（１，２−ａ）−インデノ（１，２−ｅ）ピラジン−４−オン誘導体およびそれを含む医薬組成物
NZ501094A (en) Substituted-1,2, 3-tri[4,5-c][1]benzazepine-diones as neurologically active agents
US6063803A (en) Octahydropyrrolo-[3,4-c]carbazoles useful as analgesic agents
JP2016516828A (ja) ピラジノ［１，２−ａ］インドール化合物、その調製および医薬としての使用
HUP0002109A2 (hu) (E)-4,6-diklór-3-(2-oxo-1-fenilpirrolidin-3-ilidén-metil)-1H-indol-2-karbonsav kristályos hidratált nátriumsója, eljárás előállítására és az ilyen vegyületet tartalmazó gyógyszerkészítmény
US6448249B1 (en) Substituted 1,2,4-triazolo[3,4-A]phthalazine derivatives as GABAα5 ligands
AU746719B2 (en) Substituted 1,2,4-triazolo(3,4-a)pyridazine
HK1105971B (en) Pyrrazolo-pyrimidine derivatives
MXPA00008320A (en) SUBSTITUTED 1,2,4-TRIAZOLO[3,4-a]PYRIDAZINE

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ASTRAZENECA AB

Free format text: FORMER OWNER WAS: ZENECA LIMITED

MK14 Patent ceased section 143(a) (annual fees not paid) or expired